Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Constance A Benson

Showing results (81-90 of 104) with videos related to

Pageof 11
Sort By:
Infectious Diseases and Therapy|September 15, 2024
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist VesatolimodSharon A Riddler, Constance A Benson, Cynthia Brinson, et al.
The Journal of Infectious Diseases|February 28, 2002
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patientsConstance A Benson, Steven G Deeks, Scott C Brun, et al.
Plos Neglected Tropical Diseases|May 13, 2025
Cysticercosis and neurocysticercosis in people from Mocuba district, Zambézia province: A Mozambican community-based studyJanny Mucavele, Noémia Nhancupe, Gaby Ermelindo Roberto Monteiro, et al.
JAMA|July 26, 2018
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA PanelMichael S Saag, Constance A Benson, Rajesh T Gandhi, et al.
JAMA|December 1, 2022
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA PanelRajesh T Gandhi, Roger Bedimo, Jennifer F Hoy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2020
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1Sharon A Riddler, Michael Para, Constance A Benson, et al.
Open Forum Infectious Diseases|July 12, 2022
Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2Jonathan Fintzi, Tyler Bonnett, Pablo Tebas, et al.
The Lancet. Gastroenterology & Hepatology|January 13, 2022
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trialSunil S Solomon, Sandra Wagner-Cardoso, Laura Smeaton, et al.
Open Forum Infectious Diseases|March 7, 2024
Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral TherapyCynthia L Gay, Ronald J Bosch, Ashley McKhann, et al.
JAMA|December 1, 2024
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA PanelRajesh T Gandhi, Raphael J Landovitz, Paul E Sax, et al.
Pageof 11

Showing results (81-90 of 104) with videos related to

Sort By:
Pageof 11
Infectious Diseases and Therapy|September 15, 2024
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist VesatolimodSharon A Riddler, Constance A Benson, Cynthia Brinson, et al.
The Journal of Infectious Diseases|February 28, 2002
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patientsConstance A Benson, Steven G Deeks, Scott C Brun, et al.
Plos Neglected Tropical Diseases|May 13, 2025
Cysticercosis and neurocysticercosis in people from Mocuba district, Zambézia province: A Mozambican community-based studyJanny Mucavele, Noémia Nhancupe, Gaby Ermelindo Roberto Monteiro, et al.
JAMA|July 26, 2018
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA PanelMichael S Saag, Constance A Benson, Rajesh T Gandhi, et al.
JAMA|December 1, 2022
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA PanelRajesh T Gandhi, Roger Bedimo, Jennifer F Hoy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2020
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1Sharon A Riddler, Michael Para, Constance A Benson, et al.
Open Forum Infectious Diseases|July 12, 2022
Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2Jonathan Fintzi, Tyler Bonnett, Pablo Tebas, et al.
The Lancet. Gastroenterology & Hepatology|January 13, 2022
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trialSunil S Solomon, Sandra Wagner-Cardoso, Laura Smeaton, et al.
Open Forum Infectious Diseases|March 7, 2024
Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral TherapyCynthia L Gay, Ronald J Bosch, Ashley McKhann, et al.
JAMA|December 1, 2024
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA PanelRajesh T Gandhi, Raphael J Landovitz, Paul E Sax, et al.
Pageof 11